Victoria E Fincke, Maurice Loßner, Marina Kunstreich, Nic G Reitsam, Irmengard Sax, Marlena Mucha, Felix Dorn, Lorenz C Helmschrott, Maria D Hernandez Ramirez, Sebastian Dintner, Konstantin Okonechnikov, Martin Sill, Ina Oehme, Heike Peterziel, Enrique Blanco-Carmona, Eva Sipos, Stefan Wudy, Christoph Slavetinsky, Jörg Fuchs, Bruno Märkl, Eva Jüttner, Christian Vokuhl, Michael C Frühwald, Antje Redlich, Stefan Pfister, Matthias Schlesner, Rainer Claus, Michaela Kuhlen, Pascal D Johann
Pediatric adrenocortical tumors are rare, clinically heterogeneous neoplasms with unpredictable outcomes and limited treatment options. Through integrated multi-omic analysis of 214 pediatric adrenocortical tumors combining DNA methylation profiling, transcriptomics, chromatin accessibility, and spatial deconvolution, we identify four distinct risk groups. A high-risk subgroup is characterized by CpG island hypermethylation, chromosomal instability, and dismal survival. These tumors exhibit transcriptional co-activation of WNT signalling and activator protein-1 transcriptional programs and display balanced admixture of zona glomerulosa and zona fasciculata/reticularis-like cells. Spatial analysis reveals zona glomerulosa cells as WNT signaling hubs driving intercellular crosstalk. Mechanistically, the histone deacetylase inhibitor entinostat reverses promoter methylation, silences activator protein-1 activity, and induces apoptotic reprogramming in tumor models. These findings establish a molecular framework for risk stratification and identify actionable therapeutic vulnerabilities, providing an essential resource for studying this molecularly uncharted pediatric malignancy.